Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 82804-024

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 82804-024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of duloxetine hydrochloride, showing its molecular framework including a naphthalene group, thiophene ring, and hydrochloride moiety.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine doses (20 mg, 60 mg BID, 60 mg OD) and placebo. Lines show trends of patient improvement across varying pain improvement levels.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups labeled DUL 60mg BID, DUL 60mg QD, and Placebo, showing trends in patient improvement over varying levels of pain reduction.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating their respective pain improvement profiles.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting percent improvement in pain from baseline against percentage of patients with improved pain. The graph compares Duloxetine (DUL) dosages of 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo, showing the percentage of patients experiencing pain improvement over a range of values.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph depicting the percentage of patients improved over varying percent improvements in pain from baseline (BOCF). It compares two groups: placebo and DUL 60/120 mg once daily, showing trends of patient improvement across the percent improvement scale from less than 0% to 100%.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline using BOCF method. It compares placebo and Duloxetine 60 mg once daily, with Duloxetine consistently showing higher percentages of patient improvement across the range.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine delayed-release 60/120 mg once daily versus placebo. The graph shows the trend of patient improvement across increasing levels of pain improvement, with separate lines and markers for Duloxetine and placebo groups.*

FDA Label Image

82804-024-30 (Duloxetine 14)

Label for Duloxetine Delayed-Release 40 mg capsules, containing 30 count. The label indicates each capsule contains 44.9 mg duloxetine hydrochloride USP equivalent to 40 mg duloxetine, with an orange body and blue cap capsule appearance. Manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles, Spain, and relabeled by Proficient Rx LP.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing the proportion of patients with relapse over time in days after randomization. It compares two treatments: Duloxetine delayed-release capsules and placebo. The graph shows the proportion increasing over time, with the placebo group having a higher relapse rate compared to the Duloxetine delayed-release capsules group.*

FDA Label Image

Figure 2 (Image 02)

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time in days. The graph compares placebo versus duloxetine delayed-release capsules treatment groups, illustrating relapse rates from randomization up to approximately 275 days. The placebo group shows a higher relapse proportion compared to the duloxetine delayed-release capsules group over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.